A Catalase-Like Metal-Organic Framework Nanohybrid for O2-Evolving Synergistic Chemoradiotherapy
A Catalase-Like Metal-Organic Framework Nanohybrid for O2-Evolving Synergistic Chemoradiotherapy
复制标题
DOI：
10.1002/anie.201902612
复制
发表时间：
2019-06-24
影响因子：
16.6
通讯作者：
Chen, Xiaoyuan
中科院分区：
文献类型：
--
作者：
He, Zhimei;Huang, Xiaolin;Chen, Xiaoyuan
肿瘤缺氧是目前癌症治疗的致命弱点，是耐药性和治疗效果不佳（特别是放射治疗）所不可或缺的。在这里，我们提出了一种原位催化氧化策略，在肿瘤中使用卟啉金属有机框架（MOF）-金纳米粒子（AuNPs）纳米杂化物作为治疗平台，以实现O-2-进化放化疗。修饰在MOF表面上的AuNPs有效地稳定了纳米复合材料并用作放射增敏剂，而MOF支架用作封装化疗药物阿霉素的容器。体外和体内研究证实，过氧化氢酶样纳米杂化物显著增强放射治疗效果，缓解肿瘤缺氧，实现协同抗癌功效。这种混合纳米材料显著抑制肿瘤生长，全身毒性最小化，为下一代治疗诊断纳米药物开辟了新的视野。
Tumor hypoxia, the Achilles' heel of current cancer therapies, is indispensable to drug resistance and poor therapeutic outcomes especially for radiotherapy. Here we propose an insitu catalytic oxygenation strategy in tumor using porphyrinic metal-organic framework (MOF)-gold nanoparticles (AuNPs) nanohybrid as a therapeutic platform to achieve O-2-evolving chemoradiotherapy. The AuNPs decorated on the surface of MOF effectively stabilize the nanocomposite and serve as radiosensitizers, whereas the MOF scaffold acts as a container to encapsulate chemotherapeutic drug doxorubicin. Invitro and invivo studies verify that the catalase-like nanohybrid significantly enhances the radiotherapy effect, alleviating tumor hypoxia and achieving synergistic anticancer efficacy. This hybrid nanomaterial remarkably suppresses the tumor growth with minimized systemic toxicity, opening new horizons for the next generation of theranostic nanomedicines.